Some new research has emerged for CKD sufferers dealing with secondary hyperparathyroidism. Nutritional vitamin D therapy AKA NVD is typically one of the first therapies attempted, however, the research has suggested levels need to exceed 50 ng/mL in order to reduce bone turnover and PTH markers.
During the American Society of Nephrology’s Kidney 2020 Week Reimagined virtual conference, researchers presented their findings, showing that conventional Vitamin D therapy may be lacking in therapeutic value to those kidney disease sufferers who are also struggling with hyperparathyroidism unless the dosas are adjusted accordingly.
A meta-analysis of 14 randomized trials, 9 of which compared the effects of ergocalciferol or cholecalciferol on study participants with those of placebo or no treatment at all, while the remaining 5 compared them against other active treatment methods. Baseline parathyroid hormone concentration was 144 pg/mL and mean 25-hydroxyvitamin D (25(OH)D) was 19.62 ng/mL.
According to Joel Gunnarsson, MEc, of Quality Research in Stockholm, Sweden, and colleagues, PTH declined 10.53 pg/mL from baseline to trial end and 49.74 pg/mL compared with placebo or no treatment among patients receiving cholecalciferol or ergocalciferol. Calcium levels also experienced a significant increase with nutritional vitamin D therapy, however, it didn’t have any significant effect on fibroblast growth factor or phosphate levels.
Although Nutritional Vitamin D Therapy may need to be significantly higher in order to provide therapeutic benefit, it can help CKD sufferers dealing with hyperparathyroidism. Vitamin D2 tends to provide more significant benefit than D3, but if you’re thinking of incorporating any vitamin or supplement into your healthy kidney regimen, be sure to consult your healthcare provider first.
For more of the latest on what supplements you should be taking, check out these articles: